263 related articles for article (PubMed ID: 35340165)
21. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy.
Liu X; Deng J; Zhang R; Xing J; Wu Y; Chen W; Liang B; Xing D; Xu J; Zhang M
Front Immunol; 2023; 14():1335252. PubMed ID: 38162667
[TBL] [Abstract][Full Text] [Related]
22. Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer.
Desai A; Abdayem P; Adjei AA; Planchard D
Lung Cancer; 2022 Jan; 163():96-106. PubMed ID: 34942494
[TBL] [Abstract][Full Text] [Related]
23. Antibody-drug conjugates: Promising and efficient tools for targeted cancer therapy.
Nasiri H; Valedkarimi Z; Aghebati-Maleki L; Majidi J
J Cell Physiol; 2018 Sep; 233(9):6441-6457. PubMed ID: 29319167
[TBL] [Abstract][Full Text] [Related]
24. Safety and Tolerability of Antibody-Drug Conjugates in Cancer.
Wolska-Washer A; Robak T
Drug Saf; 2019 Feb; 42(2):295-314. PubMed ID: 30649747
[TBL] [Abstract][Full Text] [Related]
25. Antibody-drug conjugates transform the outcome of individuals with low-HER2-expression advanced breast cancer.
Qu F; Lu R; Liu Q; Wu X; Huang X; Yin Y; Li W
Cancer; 2024 Apr; 130(S8):1392-1402. PubMed ID: 38271367
[TBL] [Abstract][Full Text] [Related]
26. [Advances in the treatment of anti-HER-2 antibody drug conjugates in pan-tumor with low HER-2 expression].
Wei T; Yuan P
Zhonghua Zhong Liu Za Zhi; 2024 Mar; 46(3):211-220. PubMed ID: 38494768
[TBL] [Abstract][Full Text] [Related]
27. Antibody-Drug Conjugates and Tissue-Agnostic Drug Development: An Update.
Dias E Silva D; Andriatte GM; Pestana RC
Cancer J; 2022 Nov-Dec 01; 28(6):462-468. PubMed ID: 36383909
[TBL] [Abstract][Full Text] [Related]
28. Antibody-drug conjugates (ADCs) targeting TROP-2 in lung cancer.
Belluomini L; Avancini A; Sposito M; Milella M; Rossi A; Pilotto S
Expert Opin Biol Ther; 2023; 23(11):1077-1087. PubMed ID: 36995069
[TBL] [Abstract][Full Text] [Related]
29. Antibody-drug Conjugate Targets, Drugs, and Linkers.
Teicher BA; Morris J
Curr Cancer Drug Targets; 2022; 22(6):463-529. PubMed ID: 35209819
[TBL] [Abstract][Full Text] [Related]
30. [Design of next generation antibody drug conjugates].
Zhu GD; Fu YX
Yao Xue Xue Bao; 2013 Jul; 48(7):1053-70. PubMed ID: 24133971
[TBL] [Abstract][Full Text] [Related]
31. Monomethyl auristatin E-conjugated anti-EGFR antibody inhibits the growth of human EGFR-positive non-small cell lung cancer.
Li Z; Wang M; Yu D; Luo W; Fang J; Huang C; Yao X
Cancer Chemother Pharmacol; 2019 Jul; 84(1):61-72. PubMed ID: 31037333
[TBL] [Abstract][Full Text] [Related]
32. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
[TBL] [Abstract][Full Text] [Related]
33. Novel formulations and new mechanisms of delivering chemotherapy.
Stinchcombe TE
Am Soc Clin Oncol Educ Book; 2014; ():e381-6. PubMed ID: 24857128
[TBL] [Abstract][Full Text] [Related]
34. Recent Advances in Site Specific Conjugations of Antibody Drug Conjugates (ADCs).
Gao W; Zhang J; Xiang J; Zhang L; Wu C; Dhal PK; Chen B
Curr Cancer Drug Targets; 2016; 16(6):469-79. PubMed ID: 27174056
[TBL] [Abstract][Full Text] [Related]
35. Antibody drug conjugates.
Bakhtiar R
Biotechnol Lett; 2016 Oct; 38(10):1655-64. PubMed ID: 27334710
[TBL] [Abstract][Full Text] [Related]
36. The Rise of the TROP2-Targeting Agents in NSCLC: New Options on the Horizon.
Ahmed Y; Berenguer-Pina JJ; Mahgoub T
Oncology; 2021; 99(10):673-680. PubMed ID: 34280931
[TBL] [Abstract][Full Text] [Related]
37. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
[TBL] [Abstract][Full Text] [Related]
38. [Expert consensus on the clinical application of antibody drug conjugates in the treatment of malignant tumors (2023 edition)].
; ; ;
Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):741-762. PubMed ID: 37460440
[TBL] [Abstract][Full Text] [Related]
39. The role of cetuximab and other epidermal growth factor receptor monoclonal antibodies in the treatment of advanced non-small cell lung cancer.
Rossi A; Bria E; Maione P; Palazzolo G; Falanga M; Gridelli C
Rev Recent Clin Trials; 2008 Sep; 3(3):217-27. PubMed ID: 18782080
[TBL] [Abstract][Full Text] [Related]
40. Targeting a Radiosensitizing Antibody-Drug Conjugate to a Radiation-Inducible Antigen.
Lewis CD; Singh AK; Hsu FF; Thotala D; Hallahan DE; Kapoor V
Clin Cancer Res; 2021 Jun; 27(11):3224-3233. PubMed ID: 34074654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
